A detailed history of Brinker Capital Investments, LLC transactions in Cytokinetics Inc stock. As of the latest transaction made, Brinker Capital Investments, LLC holds 4,847 shares of CYTK stock, worth $235,224. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,847
Previous 4,881 0.7%
Holding current value
$235,224
Previous $236,000 5.93%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 06, 2023

SELL
$35.77 - $51.11 $1,216 - $1,737
-34 Reduced 0.7%
4,847 $222,000
Q3 2022

Nov 01, 2022

SELL
$38.54 - $54.52 $100,011 - $141,479
-2,595 Reduced 34.71%
4,881 $236,000
Q2 2022

Jul 18, 2022

BUY
$33.93 - $48.92 $253,660 - $365,725
7,476 New
7,476 $294,000
Q1 2022

May 16, 2022

SELL
$29.74 - $46.0 $132,224 - $204,516
-4,446 Closed
0 $0
Q4 2021

Feb 08, 2022

BUY
$34.35 - $46.38 $152,720 - $206,205
4,446 New
4,446 $203,000

Others Institutions Holding CYTK

About CYTOKINETICS INC


  • Ticker CYTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,144,096
  • Market Cap $4.57B
  • Description
  • Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...
More about CYTK
Track This Portfolio

Track Brinker Capital Investments, LLC Portfolio

Follow Brinker Capital Investments, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brinker Capital Investments, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Brinker Capital Investments, LLC with notifications on news.